Kura Oncology, Inc. (KURA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KURA Stock Price Chart Interactive Chart >
KURA Price/Volume Stats
| Current price | $13.89 | 52-week high | $19.93 |
| Prev. close | $13.82 | 52-week low | $10.41 |
| Day low | $13.21 | Volume | 492,600 |
| Day high | $14.04 | Avg. volume | 748,524 |
| 50-day MA | $13.63 | Dividend yield | N/A |
| 200-day MA | $14.56 | Market Cap | 929.20M |
Kura Oncology, Inc. (KURA) Company Bio
Kura Oncology is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines for the treatment of solid tumors and blood cancers. The company was founded in 2014 and is based in La Jolla, California.
Latest KURA News From Around the Web
Below are the latest news stories about KURA ONCOLOGY INC that investors may wish to consider to help them evaluate KURA as an investment opportunity.
Kura Oncology Announces FDA Clearance of IND Application for KO-2806, a Next-Generation Farnesyl Transferase InhibitorSAN DIEGO, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the clearance by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), for the treatment of advanced solid tumors. The Company intends to evaluate safet |
An Intrinsic Calculation For Kura Oncology, Inc. (NASDAQ:KURA) Suggests It's 48% UndervaluedToday we will run through one way of estimating the intrinsic value of Kura Oncology, Inc. ( NASDAQ:KURA ) by... |
Kura Oncology Shares Fall After Updated Ziftomenib Data At ASH MeetingKura Oncology Inc (NASDAQ: KURA) announced updated clinical data from the KOMET-001 Phase 1/2 trial of ziftomenib in patients with relapsed/refractory acute myeloid leukemia (AML). Ziftomenib demonstrated optimal clinical benefit at 600 mg with a 30% CR rate (6/20) in patients with NPM1-mutant AML, compared to 17% (1/6) at 200 mg. Notably, four NPM1-mutant patients who achieved a CR at 600 mg had IDH and/or FLT3 co-mutations. Related: Kura Oncology Reports Preliminary Proof Of Mechanism Data Fro |
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600 mg –– 600 mg determined as recommended Phase 2 dose for ziftomenib in NPM1-mutant AML following positive Type C meeting with FDA –– Company expects to dose first patient in Phase 2 registration-directed trial in NPM1-mutant AML in first quarter of 2023 –– Further clinical development of KTM2A- |
Wall Street Analysts Believe Kura Oncology (KURA) Could Rally 111%: Here's is How to TradeThe consensus price target hints at an 110.5% upside potential for Kura Oncology (KURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
KURA Price Returns
| 1-mo | 15.27% |
| 3-mo | -3.94% |
| 6-mo | -10.33% |
| 1-year | 4.04% |
| 3-year | 18.82% |
| 5-year | -29.85% |
| YTD | 11.93% |
| 2022 | -11.36% |
| 2021 | -57.13% |
| 2020 | 137.53% |
| 2019 | -2.07% |
| 2018 | -8.24% |
Loading social stream, please wait...